← Human Trials & Peer-Reviewed Studies
The Relationship Between Calciotropic Hormones, IGF-1, and Bone Mass Across Pubertal Stages
Plain-language guide to PMID 27676398 (2016): randomized controlled trial study of IGF-1 LR3 in 335 children.
Key Facts
- PMID
- 27676398
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Matar M et al. (8 authors)
- DOI
- 10.1210/jc.2016-3071
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at IGF-1 LR3.
Investigate changes in calciotropic hormones, IGF-1, body composition, and their associations with bone metabolism in adolescents.
ANOVA and regression analyses were implemented to evaluate changes in variables of interest across pubertal stages, within and between genders.
Why It Was Studied
Little is known about the changes in calciotropic hormones during puberty and their relationship to bone mass during this critical period for skeletal accretion.
Who Took Part
According to the abstract, 335 children were involved.
By PubMed's age tags, the people studied were children and teenagers, both men and women.
Post hoc analyses were performed from data on 335 healthy school children, ages 10-17 years, with hypovitaminosis D who participated in a vitamin D randomized controlled trial.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Baseline serum biochemistries; hormonal studies; densitometry at the spine, hip, and total body; and body composition were used.
What Was Measured
The subject headings attached to it are Alkaline Phosphatase, Body Composition, Bone Density, Insulin-Like Growth Factor I, Osteocalcin, Parathyroid Hormone and Phosphorus.
What This Means in Plain Language
The paper is a randomized study of IGF-1 LR3 in 335 children.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2016 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.